Outcome of Patients Treated with Oral Sofosbuvir and Ribavirin: One Year Follow up Experience
Objective: The aim of this study was to evaluate the efficacy and safety of sofosbuvir plus ribavirin therapy and prevalence of hepatitis C relapses.
Methodology: A descriptive case series study was planned and executed for the evaluation efficacy, safety and relapsers of among HCV patients treated with sofosbuvir plus ribavirin. One hundred patients were enrolled after careful monitoring of inclusion criteria. PCR, LFTs, CP, RFTs, Serum albumin and ultrasound performed in all patients and they were given 400mg of sofosbuvir and 1000mg of Ribavarin. There was no dropout of haemoglobin and ALT was normalized in both groups.
Results: 69% male and 31% females between January 2014 to March 2017. All patients were naive having genotype 3 and average age in males being 33.3 years whilst in females being 51.61 years. At one-month post treatment, 87.09% females and 78.265% males achieved RVR while ETR was 83.87% in females and 86.95% in males. Treatment related adverse effects were myalgias, insomnia and flu like symptoms which need symptomatic treatment. After 3 months of follow up, SVR was observed to be 90.32% in females and 88.405% in males. However, subsequent follow up of 1 patients revealed a relapse rate of 12.9% in females and 8.69% in males after achieving SVR.
Conclusion: The combination of sofosbuvir and ribavarin is safe and effective treatment for genotype 3 (GT3) non cirrhotic patients